Shao-Sung Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shao-Sung Huang has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Po-Hsun Huang
Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
5 shared publications - Jaw-Wen Chen
Department and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan
4 shared publications - Hsin-Bang Leu
Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou Dist., Taipei City, Taiwan
3 shared publications Shing-Jong Lin
Affiliations Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Healthcare and Management Center, Taipei Veterans General Hospital, Taipei, Taiwan, Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Tainan City, Taiwan
3 shared publications- Cheng-Chien Lai
Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
2 shared publications - Cheng-Hsueh Wu
Division of Cardiology Department of Medicine Taipei Veterans General Hospital Taipei Taiwan
2 shared publications
Latest Publications
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e047499
Graded Associations Between Left Ventricular Ejection Fraction Improvement and Cardiorenal Outcomes in Heart Failure With Improved Ejection Fraction
Background: Improvement in left ventricular ejection fraction (LVEF) aligns with better outcomes in patients with heart failure with reduced EF. Nonetheless, detailed relationship between the extent of LVEF improvement and the risks of adverse cardiorenal events remains unclear. Methods: From 2011 to 2021, a retrospective cohort of 601 patients with heart failure with reduced EF who underwent follow‐up echocardiography within 6 months was enrolled and followed until March 31, 2022. Patients were classified as nonimprovement (follow‐up LVEF ≤40% or 40% with 10% to 40% and ≥20% improvement). Multivariable Cox regression was used to estimate associations between LVEF improvement and the composite and individual risks of all‐cause mortality, major adverse cardiovascular events, and major adverse kidney events. Results: Over a median follow‐up of 2.62 years, 67 deaths, 121 major adverse cardiovascular events, and 100 major adverse kidney events occurred. Compared with the nonimprovement group, only the full‐improvement group was independently associated with lower risks of the composite outcome (adjusted hazard ratio [aHR], 0.36 [95% CI, 0.20–0.63]), major adverse cardiovascular events (aHR, 0.33 [95% CI, 0.18–0.61]), and major adverse kidney events (aHR, 0.39 [95% CI, 0.19–0.82]). Graded associations between LVEF improvement and decreased cardiorenal risks were confirmed in spline analyses and consistent across subgroup and sensitivity analyses. Maintenance of improved LVEF for 1 year was further associated with lower risks for the adverse cardiorenal outcomes. Conclusions: Greater and sustained LVEF improvement is linked to lower risks of cardiorenal events in heart failure with reduced EF, emphasizing the value of incorporating improvement magnitude into risk assessment.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e047499
Graded Associations Between Left Ventricular Ejection Fraction Improvement and Cardiorenal Outcomes in Heart Failure With Improved Ejection Fraction
Background: Improvement in left ventricular ejection fraction (LVEF) aligns with better outcomes in patients with heart failure with reduced EF. Nonetheless, detailed relationship between the extent of LVEF improvement and the risks of adverse cardiorenal events remains unclear. Methods: From 2011 to 2021, a retrospective cohort of 601 patients with heart failure with reduced EF who underwent follow‐up echocardiography within 6 months was enrolled and followed until March 31, 2022. Patients were classified as nonimprovement (follow‐up LVEF ≤40% or 40% with 10% to 40% and ≥20% improvement). Multivariable Cox regression was used to estimate associations between LVEF improvement and the composite and individual risks of all‐cause mortality, major adverse cardiovascular events, and major adverse kidney events. Results: Over a median follow‐up of 2.62 years, 67 deaths, 121 major adverse cardiovascular events, and 100 major adverse kidney events occurred. Compared with the nonimprovement group, only the full‐improvement group was independently associated with lower risks of the composite outcome (adjusted hazard ratio [aHR], 0.36 [95% CI, 0.20–0.63]), major adverse cardiovascular events (aHR, 0.33 [95% CI, 0.18–0.61]), and major adverse kidney events (aHR, 0.39 [95% CI, 0.19–0.82]). Graded associations between LVEF improvement and decreased cardiorenal risks were confirmed in spline analyses and consistent across subgroup and sensitivity analyses. Maintenance of improved LVEF for 1 year was further associated with lower risks for the adverse cardiorenal outcomes. Conclusions: Greater and sustained LVEF improvement is linked to lower risks of cardiorenal events in heart failure with reduced EF, emphasizing the value of incorporating improvement magnitude into risk assessment.
- Open Access
- 18 August 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (8) , e0272258
Effect of timing of coronary revascularization in patients with post-infectious myocardial infarction
Objectives: Acute infection is a well-known provocative factor of acute myocardial infarction (AMI). Prognosis is worse when it is associated with sepsis. Coronary revascularization is reported to provide benefit in these patients; however, the optimal timing remains uncertain. Methods: This retrospective study was performed at a tertiary center in Taipei from January 2010 to December 2017. 1931 patients received coronary revascularization indicated for AMI. Among these, 239 patients were hospitalized for acute infection but later developed AMI. Patients with either an ST-elevation myocardial infarct or the absence of obstructive coronary artery disease were excluded. Revascularization was performed via either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG). We defined early and delayed revascularization groups if it was performed within or after 24 hours of the diagnosis of AMI, respectively. We evaluated whether the timing of revascularization altered 30-day and one-year all-cause mortality. Results: At one month, 24 (26%) patients died in early revascularization group and 32 (22%) patients in delayed revascularization group. At one year, 40 (43%) and 59 (40%) patients died on early and delayed revascularization groups respectively. Early revascularization did not result in lower 30-day all-cause mortality (P = 0.424), and one-year all-cause mortality (Hazard ratio (HR): 0.935; 95% confidence interval (CI): 0.626–1.397, P = 0.742) than delay revascularization. Conclusions: Timing of coronary revascularization of post infectious acute coronary syndrome may be arranged according to individual risk category as those without sepsis.
- 18 August 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (8) , e0272258
Open AccessEffect of timing of coronary revascularization in patients with post-infectious myocardial infarction
Objectives: Acute infection is a well-known provocative factor of acute myocardial infarction (AMI). Prognosis is worse when it is associated with sepsis. Coronary revascularization is reported to provide benefit in these patients; however, the optimal timing remains uncertain. Methods: This retrospective study was performed at a tertiary center in Taipei from January 2010 to December 2017. 1931 patients received coronary revascularization indicated for AMI. Among these, 239 patients were hospitalized for acute infection but later developed AMI. Patients with either an ST-elevation myocardial infarct or the absence of obstructive coronary artery disease were excluded. Revascularization was performed via either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG). We defined early and delayed revascularization groups if it was performed within or after 24 hours of the diagnosis of AMI, respectively. We evaluated whether the timing of revascularization altered 30-day and one-year all-cause mortality. Results: At one month, 24 (26%) patients died in early revascularization group and 32 (22%) patients in delayed revascularization group. At one year, 40 (43%) and 59 (40%) patients died on early and delayed revascularization groups respectively. Early revascularization did not result in lower 30-day all-cause mortality (P = 0.424), and one-year all-cause mortality (Hazard ratio (HR): 0.935; 95% confidence interval (CI): 0.626–1.397, P = 0.742) than delay revascularization. Conclusions: Timing of coronary revascularization of post infectious acute coronary syndrome may be arranged according to individual risk category as those without sepsis.
- Open Access
Association between Coronary Artery Plaque Progression and Liver Fibrosis Biomarkers in Population with Low Calcium Scores
Background: The severity of nonalcoholic fatty liver disease (NAFLD) has been found to be associated with atherosclerosis burden. However, whether liver fibrosis scores can be used to predict atherosclerosis progression, especially for patients with low calcium scores, remains undetermined. Methods: A total of 165 subjects who underwent repeated coronary computed tomography angiography (CCTA) and had low calcium scores (<100) were enrolled. The segment stenosis score (SSS) from the CCTA was measured, and the association between SSS progression and biochemical parameters was analyzed in addition to liver fibrosis scores, including nonalcoholic fatty liver disease fibrosis score (NFS), fibrosis-4 index (FIB-4), aspartate aminotransferase (AST) to platelet ratio index (APRI), and Forns score. Results: When compared with those without plaque at baseline (SSS = 0), subjects with plaque had higher blood pressure, higher coronary artery calcium (CAC) scores, and higher liver fibrosis scores, including Forns score, Fib-4, and NFS. During the medium follow-up interval of 24.7 months, 60 (39.4%) patients displayed SSS progression, while the remaining 105 (63.6%) patients showed no CAD progression. In a multivariate analysis, being male having a high diastolic blood pressure (DBP), and having a high NFS liver fibrosis score were independently associated with the odds ratio for SSS progression. Conclusions: Higher baseline blood pressure and liver fibrosis markers are associated with the presence of coronary artery disease (CAD) plaques in subjects in early CAD stages. For disease progression, the male gender, DBP, and NFS appear to be independently associated with coronary atherosclerosis plaque progression in subjects with low calcium scores.
Open AccessAssociation between Coronary Artery Plaque Progression and Liver Fibrosis Biomarkers in Population with Low Calcium Scores
Background: The severity of nonalcoholic fatty liver disease (NAFLD) has been found to be associated with atherosclerosis burden. However, whether liver fibrosis scores can be used to predict atherosclerosis progression, especially for patients with low calcium scores, remains undetermined. Methods: A total of 165 subjects who underwent repeated coronary computed tomography angiography (CCTA) and had low calcium scores (<100) were enrolled. The segment stenosis score (SSS) from the CCTA was measured, and the association between SSS progression and biochemical parameters was analyzed in addition to liver fibrosis scores, including nonalcoholic fatty liver disease fibrosis score (NFS), fibrosis-4 index (FIB-4), aspartate aminotransferase (AST) to platelet ratio index (APRI), and Forns score. Results: When compared with those without plaque at baseline (SSS = 0), subjects with plaque had higher blood pressure, higher coronary artery calcium (CAC) scores, and higher liver fibrosis scores, including Forns score, Fib-4, and NFS. During the medium follow-up interval of 24.7 months, 60 (39.4%) patients displayed SSS progression, while the remaining 105 (63.6%) patients showed no CAD progression. In a multivariate analysis, being male having a high diastolic blood pressure (DBP), and having a high NFS liver fibrosis score were independently associated with the odds ratio for SSS progression. Conclusions: Higher baseline blood pressure and liver fibrosis markers are associated with the presence of coronary artery disease (CAD) plaques in subjects in early CAD stages. For disease progression, the male gender, DBP, and NFS appear to be independently associated with coronary atherosclerosis plaque progression in subjects with low calcium scores.
- 23 October 2021
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (2) , e13698
Obesity paradox in patients with chronic total occlusion of coronary artery
Background: Obesity is associated with metabolic syndrome which increases further risk of coronary artery disease and adverse cardiovascular events. Impact of body mass index (BMI) on long‐term outcome in patients with coronary chronic total occlusion (CTO) is less clear.Method and results: From January 2005 to November 2020, a total of 1301 patients with coronary angiographic confirmed CTO were enrolled in our study. Patients were divided into two groups: low BMI group: 18–24.99 kg/m2 and high BMI group ≥25 kg/m2. Clinical outcomes were 3‐year all‐cause mortality, 3‐year cardiovascular mortality and 3‐year non‐fatal myocardial infarct. During the 3‐year follow‐up period, all‐cause mortality was significantly higher in patients with low BMI group compared to those in high BMI groups (14% vs. 6%, p = .0001). Kaplan–Meier analysis showed patients with high BMI groups had significant better survival compared with those in low BMI group (p = .0001). In multivariate analysis, higher BMI was independently associated with decreased risk of 3‐year all‐cause mortality (Hazard ratio [HR]: 0.534; 95% confidence interval [CI]: 0.349–0.819, p = .004) after controlling for age, renal function, prior history of stroke, coronary artery bypass graft, co‐morbidities with peripheral arterial disease, heart failure and revascularization status for CTO. In propensity‐matched multivariate analysis, high BMI remained a significant predictor of 3‐year all‐cause mortality (HR, 0.525; 95% CI, 0.346–0.795, p = .002).Conclusion: Higher BMI was associated with better long‐term outcome in patients with coronary CTO.
- 23 October 2021
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (2) , e13698
Obesity paradox in patients with chronic total occlusion of coronary artery
Background: Obesity is associated with metabolic syndrome which increases further risk of coronary artery disease and adverse cardiovascular events. Impact of body mass index (BMI) on long‐term outcome in patients with coronary chronic total occlusion (CTO) is less clear.Method and results: From January 2005 to November 2020, a total of 1301 patients with coronary angiographic confirmed CTO were enrolled in our study. Patients were divided into two groups: low BMI group: 18–24.99 kg/m2 and high BMI group ≥25 kg/m2. Clinical outcomes were 3‐year all‐cause mortality, 3‐year cardiovascular mortality and 3‐year non‐fatal myocardial infarct. During the 3‐year follow‐up period, all‐cause mortality was significantly higher in patients with low BMI group compared to those in high BMI groups (14% vs. 6%, p = .0001). Kaplan–Meier analysis showed patients with high BMI groups had significant better survival compared with those in low BMI group (p = .0001). In multivariate analysis, higher BMI was independently associated with decreased risk of 3‐year all‐cause mortality (Hazard ratio [HR]: 0.534; 95% confidence interval [CI]: 0.349–0.819, p = .004) after controlling for age, renal function, prior history of stroke, coronary artery bypass graft, co‐morbidities with peripheral arterial disease, heart failure and revascularization status for CTO. In propensity‐matched multivariate analysis, high BMI remained a significant predictor of 3‐year all‐cause mortality (HR, 0.525; 95% CI, 0.346–0.795, p = .002).Conclusion: Higher BMI was associated with better long‐term outcome in patients with coronary CTO.
- Open Access
- 23 July 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (7) , e0254835
Significance of serum FGF-23 for risk assessment of contrast-associated acute kidney injury and clinical outcomes in patients undergoing coronary angiography
Background: Fibroblast growth factor (FGF)-23 levels rise as kidney function declines. Whether elevated FGF-23 levels are associated with an increased risk for contrast-associated acute kidney injury (CA-AKI) and major adverse cardiovascular events (MACE) in patients undergoing coronary angiography remain uncertain. Methods: In total, 492 patients receiving coronary angiography were enrolled. Their serum FGF-23 levels were measured before administration of contrast media. The occurrence of CA-AKI was defined as a rise in serum creatinine of 0.5 mg/dL or a 25% increase from the baseline value within 48 h after the procedure. All patients were followed up for at least 1 year or until the occurrence of MACE including death, nonfatal myocardial infarction (MI), and ischemic stroke. Results: Overall, CA-AKI occurred in 41 (8.3%) patients. During a median follow-up of 2.6 years, there were 24 deaths, 3 nonfatal MIs, and 7 ischemic strokes. Compared with those in the lowest FGF-23 tertile, individuals in the highest FGF-23 tertile had a significantly higher incidence of CA-AKI (P < 0.001) and lower incidence of MACE-free survival (P = 0.001). In multivariate regression analysis, higher FGF-23 level was found to be independently associated with a graded risk for CA-AKI (OR per doubling, 1.90; 95% CI 1.48–2.44) and MACE (HR per doubling, 1.25; 95% CI 1.02–1.52). Conclusions: Elevated FGF-23 levels were associated with an increased risk for CA-AKI and future MACE among patients undergoing coronary angiography. FGF-23 may play a role in early diagnosis of CA-AKI and predicting clinical outcomes after coronary angiography.
- 23 July 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (7) , e0254835
Open AccessSignificance of serum FGF-23 for risk assessment of contrast-associated acute kidney injury and clinical outcomes in patients undergoing coronary angiography
Background: Fibroblast growth factor (FGF)-23 levels rise as kidney function declines. Whether elevated FGF-23 levels are associated with an increased risk for contrast-associated acute kidney injury (CA-AKI) and major adverse cardiovascular events (MACE) in patients undergoing coronary angiography remain uncertain. Methods: In total, 492 patients receiving coronary angiography were enrolled. Their serum FGF-23 levels were measured before administration of contrast media. The occurrence of CA-AKI was defined as a rise in serum creatinine of 0.5 mg/dL or a 25% increase from the baseline value within 48 h after the procedure. All patients were followed up for at least 1 year or until the occurrence of MACE including death, nonfatal myocardial infarction (MI), and ischemic stroke. Results: Overall, CA-AKI occurred in 41 (8.3%) patients. During a median follow-up of 2.6 years, there were 24 deaths, 3 nonfatal MIs, and 7 ischemic strokes. Compared with those in the lowest FGF-23 tertile, individuals in the highest FGF-23 tertile had a significantly higher incidence of CA-AKI (P < 0.001) and lower incidence of MACE-free survival (P = 0.001). In multivariate regression analysis, higher FGF-23 level was found to be independently associated with a graded risk for CA-AKI (OR per doubling, 1.90; 95% CI 1.48–2.44) and MACE (HR per doubling, 1.25; 95% CI 1.02–1.52). Conclusions: Elevated FGF-23 levels were associated with an increased risk for CA-AKI and future MACE among patients undergoing coronary angiography. FGF-23 may play a role in early diagnosis of CA-AKI and predicting clinical outcomes after coronary angiography.
- Open Access
- 26 November 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-10
Galectin-1 is associated with the severity of coronary artery disease and adverse cardiovascular events in patients undergoing coronary angiography
Galectin-1, a β-galactoside-binding lectin mediating inflammation and neovascularization, is reported to attenuate ventricular remodeling after myocardial infarction. But its role in stable coronary artery disease (CAD) has not been fully elucidated. This study aimed to identify the relationship between the circulating galectin-1 level and the severity of CAD in patients with suspected CAD. Pre-procedure galectin-1 and high-sensitivity C-reactive protein (hs-CRP) concentrations were measured in 834 subjects who underwent scheduled coronary angiography. Subjects were grouped into tertiles of the galectin-1 levels. SYNTAX scores were calculated to evaluate the severity of CAD. All patients were followed until January 2019 or the occurrence of major adverse cardiovascular events (MACE). Patients with higher galectin-1 concentrations were older; had greater prevalence of hypertension, diabetes, chronic kidney disease, and heart failure; and were more likely to present with higher hs-CRP levels and SYNTAX scores. During the follow-up period of 1.3 ± 1.1 years, patients in the highest tertile of galectin-1 were associated with a greater risk of MACE after adjustment for age, sex, comorbidities, co-medications, serum levels of hemoglobin, creatinine, hs-CRP, ejection fraction, SYNTAX scores, and revascularization modalities (adjusted hazard ratio 10.95, 95% confidence interval 2.29–52.47, p = 0.003). Galectin-1 showed better discriminatory performance than hs-CRP, and non-inferior performance to SYNTAX scores, in predicting the incidence of MACE.
- 26 November 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-10
Open AccessGalectin-1 is associated with the severity of coronary artery disease and adverse cardiovascular events in patients undergoing coronary angiography
Galectin-1, a β-galactoside-binding lectin mediating inflammation and neovascularization, is reported to attenuate ventricular remodeling after myocardial infarction. But its role in stable coronary artery disease (CAD) has not been fully elucidated. This study aimed to identify the relationship between the circulating galectin-1 level and the severity of CAD in patients with suspected CAD. Pre-procedure galectin-1 and high-sensitivity C-reactive protein (hs-CRP) concentrations were measured in 834 subjects who underwent scheduled coronary angiography. Subjects were grouped into tertiles of the galectin-1 levels. SYNTAX scores were calculated to evaluate the severity of CAD. All patients were followed until January 2019 or the occurrence of major adverse cardiovascular events (MACE). Patients with higher galectin-1 concentrations were older; had greater prevalence of hypertension, diabetes, chronic kidney disease, and heart failure; and were more likely to present with higher hs-CRP levels and SYNTAX scores. During the follow-up period of 1.3 ± 1.1 years, patients in the highest tertile of galectin-1 were associated with a greater risk of MACE after adjustment for age, sex, comorbidities, co-medications, serum levels of hemoglobin, creatinine, hs-CRP, ejection fraction, SYNTAX scores, and revascularization modalities (adjusted hazard ratio 10.95, 95% confidence interval 2.29–52.47, p = 0.003). Galectin-1 showed better discriminatory performance than hs-CRP, and non-inferior performance to SYNTAX scores, in predicting the incidence of MACE.
- Open Access
Association between Preoperative Nutritional Status and Clinical Outcomes of Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Background: Malnutrition is associated with poor outcomes in patients with cancer, heart failure and chronic kidney disease. This study aimed to investigate the predictive value of the Controlling Nutritional Status (CONUT) score in coronary artery disease (CAD) patients. Methods: We recruited a cohort of 3118 patients with CAD undergoing percutaneous coronary intervention (PCI) from 2005 to 2015. Nutritional status was evaluated using the CONUT score, with higher scores reflecting worse nutritional status. Results: After adjustment for comorbidities and medication, an increased CONUT score was independently associated with a higher risk of acute myocardial infarction (AMI) (HR: 1.13; 95% CI: 1.03–1.24), cardiovascular (CV) death (HR: 1.18; 95% CI: 1.07–1.30), congestive heart failure (CHF) (HR: 1.11; 95% CI: 1.04–1.18), a major adverse cardiovascular event (MACE) (HR: 1.14; 95% CI: 1.07–1.22), and total CV events (HR: 1.11; 95% CI: 1.07–1.15). The subgroup analyses demonstrated that the association of the CONUT score existed independently of other established cardiovascular risk factors. In addition, CONUT significantly improved risk stratification for myocardial infarction (MI), cardiac death, CHF, MACEs and total CV events compared to conventional risk factors in CAD patients by the significant increase in the C-index (p < 0.05) and reclassification risk categories in cardiac death and MACEs. Conclusions: The CONUT score improved the risk prediction of adverse events compared to traditional risk factors in CAD patients after percutaneous coronary intervention (PCI).
Open AccessAssociation between Preoperative Nutritional Status and Clinical Outcomes of Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Background: Malnutrition is associated with poor outcomes in patients with cancer, heart failure and chronic kidney disease. This study aimed to investigate the predictive value of the Controlling Nutritional Status (CONUT) score in coronary artery disease (CAD) patients. Methods: We recruited a cohort of 3118 patients with CAD undergoing percutaneous coronary intervention (PCI) from 2005 to 2015. Nutritional status was evaluated using the CONUT score, with higher scores reflecting worse nutritional status. Results: After adjustment for comorbidities and medication, an increased CONUT score was independently associated with a higher risk of acute myocardial infarction (AMI) (HR: 1.13; 95% CI: 1.03–1.24), cardiovascular (CV) death (HR: 1.18; 95% CI: 1.07–1.30), congestive heart failure (CHF) (HR: 1.11; 95% CI: 1.04–1.18), a major adverse cardiovascular event (MACE) (HR: 1.14; 95% CI: 1.07–1.22), and total CV events (HR: 1.11; 95% CI: 1.07–1.15). The subgroup analyses demonstrated that the association of the CONUT score existed independently of other established cardiovascular risk factors. In addition, CONUT significantly improved risk stratification for myocardial infarction (MI), cardiac death, CHF, MACEs and total CV events compared to conventional risk factors in CAD patients by the significant increase in the C-index (p < 0.05) and reclassification risk categories in cardiac death and MACEs. Conclusions: The CONUT score improved the risk prediction of adverse events compared to traditional risk factors in CAD patients after percutaneous coronary intervention (PCI).
- 1 November 2013
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 31 (11) , 2187-2194
Association of central pulse pressure with contrast-induced nephropathy and clinical outcomes in patients undergoing coronary intervention
The increase in pulse pressure (PP) may be transmitted to the glomerulus and thus impair renal blood flow autoregulation. This subtle change could predispose patients to the detrimental effect of contrast media. We sought to determine whether elevated central PP is associated with increased contrast-induced nephropathy (CIN) and future cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). In total, 448 consecutive patients receiving PCI were enrolled. In each patient, central and peripheral blood pressures were measured before PCI. The occurrence of CIN was identified and defined as a rise in serum creatinine of 0.5 mg/dl or a 25% increase from the baseline value within 48 h after the procedure. All patients were then followed up for at least 3 years or until the occurrence of a major adverse cardiovascular event (MACE) including death, nonfatal myocardial infarction, and ischemic stroke after coronary intervention. Overall, CIN occurred in 52 (11.6%) patients. Patients developing CIN had higher baseline central PP (P = 0.004). Patients were then stratified into three groups (low/intermediate/high) according to baseline central PP. Compared to that with the lowest tertile of central PP, patients with the highest tertile of central PP had a significantly increased incidence of CIN after PCI (odds ratio, 2.94; 95% confidence interval, CI 1.02-8.51). By Cox regression analysis, elevated central PP was an independent predictor of future MACE in all patients undergoing PCI (hazard ratio, 2.07; 95% CI 1.04-4.12). Elevated baseline central PP was associated with an increased risk of CIN and future cardiovascular events in patients with PCI. Further clinical study may be indicated to determine whether pharmacological modulation on baseline central PP could prevent CIN and future MACE after PCI.
- 1 November 2013
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 31 (11) , 2187-2194
Association of central pulse pressure with contrast-induced nephropathy and clinical outcomes in patients undergoing coronary intervention
The increase in pulse pressure (PP) may be transmitted to the glomerulus and thus impair renal blood flow autoregulation. This subtle change could predispose patients to the detrimental effect of contrast media. We sought to determine whether elevated central PP is associated with increased contrast-induced nephropathy (CIN) and future cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). In total, 448 consecutive patients receiving PCI were enrolled. In each patient, central and peripheral blood pressures were measured before PCI. The occurrence of CIN was identified and defined as a rise in serum creatinine of 0.5 mg/dl or a 25% increase from the baseline value within 48 h after the procedure. All patients were then followed up for at least 3 years or until the occurrence of a major adverse cardiovascular event (MACE) including death, nonfatal myocardial infarction, and ischemic stroke after coronary intervention. Overall, CIN occurred in 52 (11.6%) patients. Patients developing CIN had higher baseline central PP (P = 0.004). Patients were then stratified into three groups (low/intermediate/high) according to baseline central PP. Compared to that with the lowest tertile of central PP, patients with the highest tertile of central PP had a significantly increased incidence of CIN after PCI (odds ratio, 2.94; 95% confidence interval, CI 1.02-8.51). By Cox regression analysis, elevated central PP was an independent predictor of future MACE in all patients undergoing PCI (hazard ratio, 2.07; 95% CI 1.04-4.12). Elevated baseline central PP was associated with an increased risk of CIN and future cardiovascular events in patients with PCI. Further clinical study may be indicated to determine whether pharmacological modulation on baseline central PP could prevent CIN and future MACE after PCI.